Shorepower Technologies, Inc. (OTC: SPEV) has entered into a merger agreement with Aeternum Health LLC that will fundamentally transform the company's strategic direction from transportation electrification infrastructure to a longevity-focused healthcare platform. The transaction, structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code, represents a complete pivot for the publicly traded company.
Under the terms of the agreement, Aeternum Health will merge with and into Shorepower, with Shorepower continuing as the surviving entity. The sole member of Aeternum Health will receive common stock representing 51% ownership of the combined company, effectively gaining control. Additionally, the transaction includes the issuance of 2,000,000 shares of Series B Preferred Stock, with each share having voting power equal to 40 shares of common stock, further consolidating control in the hands of Aeternum Health's leadership.
The strategic implications of this merger are substantial for both companies and the broader healthcare industry. Shorepower will transition from designing and operating transportation electrification equipment to developing services, products, and solutions designed to increase longevity and optimize health outcomes. This shift reflects growing investor and market interest in longevity science and anti-aging technologies, particularly peptide-based interventions that target fundamental aging processes.
As part of the transaction, Aeternum Health will contribute several key assets to the combined entity. These include know-how and data relating to a novel peptide mix in development for longevity and anti-aging applications, along with associated intellectual property. The company will also contribute a minimum of $1.5 million in cash and a business related to the commercialization of the peptide technology. These contributions provide both the scientific foundation and financial resources necessary to pursue the new strategic direction.
Leadership changes accompany the strategic shift, with Jeff Kim resigning as President, Chief Executive Officer, and sole director of Shorepower. Paul E. Mann, Manager of Aeternum Health, will assume the roles of President, Chief Executive Officer, and sole member of the Board of Directors upon closing of the merger. Mann brings over two decades of experience in biotechnology, healthcare investing, and public company leadership, including his current role as Chairman and CEO of ASP Isotopes Inc. (Nasdaq: ASPI). His background includes senior investment roles at Soros Fund Management, Highbridge Capital, and DSAM Partners, where he managed significant capital allocations in healthcare and biotechnology sectors.
The corporate restructuring includes several planned actions following the merger completion. The company intends to change its name to Aeternum Health Inc. and increase its authorized common shares to 250 million. Additionally, Shorepower's existing transportation electrification business will be spun out, completely separating the legacy operations from the new longevity-focused platform. Financial statements and pro forma financial information relating to Aeternum Health will be filed by amendment within 71 calendar days of the initial Form 8-K filing.
For business and technology leaders, this merger represents a notable example of a public company executing a complete strategic pivot through acquisition. The transaction demonstrates how established companies can rapidly enter emerging technology sectors by merging with specialized private entities. The longevity and health optimization market represents a significant growth opportunity as demographic shifts and scientific advances create demand for interventions that extend healthspan and improve quality of life in aging populations.
The forward-looking statements in the announcement acknowledge several risks that could affect the transaction's completion and success. These include the ability to consummate the merger, regulatory and stockholder approvals, integration risks, financing availability, development and commercialization risks, intellectual property risks, market acceptance, and general economic conditions. The company cautions readers not to place undue reliance on forward-looking statements, which speak only as of the date of the release.
